Biocon Inks Agreement with Biomm SA to Distribute Diabetes Medication in Brazil
Biocon entered into an exclusive licensing and supply agreement with Biomm SA of Brazil, enabling Biomm to commercialize Biocon’s drug Semaglutide (marketed as ozempic) for the management of type 2 diabetes in adults. Biocon will handle the development, …